BeOne Medicines settles China tax audit; pays ~RMB 446M in Q2 2026

BeOne Medicines Ltd.

Settled statutory tax audit in China; payment of approx. RMB 446 million (including surcharges and interest) to be recognized in Q2 2026.
No administrative penalty imposed; adjustments to previously filed tax returns agreed with local tax authority.
The payment resolves an uncertain tax position previously disclosed in the Q1 2026 10-Q filing.
Approximate USD equivalent ~$62M based on current exchange rates; cash flow impact in 2Q 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.